HIF-mediated innate immune responses: cell signaling and therapeutic implications by AJ, Harris et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIF-mediated innate immune responses: cell signaling and
therapeutic implications
Citation for published version:
AJ, H, Thompson, AAR, Whyte, M & Walmsley, S 2014, 'HIF-mediated innate immune responses: cell
signaling and therapeutic implications' Hypoxia, vol. 2, pp. 47-58. DOI: 10.2147/HP.S50269
Digital Object Identifier (DOI):
10.2147/HP.S50269
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Hypoxia
Publisher Rights Statement:
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non
Commercial (unported, v3.0) License. The full terms of the License are available at
http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any
further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions
beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to
request permission may be found at: http://www.dovepress.com/permissions.php
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
© 2014 Harris et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Hypoxia 2014:2 47–58
Hypoxia Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
47
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/HP.S50269
HiF-mediated innate immune responses:  
cell signaling and therapeutic implications
Alison J Harris
AA Roger Thompson
Moira KB whyte
Sarah R walmsley
Academic Unit of Respiratory  
Medicine, Department of  
infection and immunity, University  
of Sheffield, Sheffield, UK
Correspondence: Sarah R walmsley 
Academic Unit of Respiratory Medicine,  
The Medical School, University of  
Sheffield, Sheffield S10 2RX, UK 
Tel +44 1142 711 725 
Fax +44 1142 268 898 
email s.walmsley@sheffield.ac.uk
Abstract: Leukocytes recruited to infected, damaged, or inflamed tissues during an immune 
response must adapt to oxygen levels much lower than those in the circulation. Hypoxia induc-
ible factors (HIFs) are key mediators of cellular responses to hypoxia and, as in other cell types, 
HIFs are critical for the upregulation of glycolysis, which enables innate immune cells to produce 
adenosine triphosphate anaerobically. An increasing body of evidence demonstrates that hypoxia 
also regulates many other innate immunological functions, including cell migration, apoptosis, 
phagocytosis of pathogens, antigen presentation and production of cytokines, chemokines, and 
angiogenic and antimicrobial factors. Many of these functions are mediated by HIFs, which 
are not only stabilized posttranslationally by hypoxia, but also transcriptionally upregulated 
by inflammatory signals. Here, we review the role of HIFs in the responses of innate immune 
cells to hypoxia, both in vitro and in vivo, with a particular focus on myeloid cells, on which 
the majority of studies have so far been carried out.
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Introduction
Innate immune cells include both myeloid cells, such as neutrophils and circulating 
monocytes which differentiate into macrophages within tissues, and innate lymphoid 
cells (ILCs). These cells have important functions in host defense, including the 
 phagocytosis of pathogens, the release of antimicrobial proteases, and the secre-
tion of cytokines and chemokines that attract and activate other immune cells. Cells 
of the immune system encounter a range of different oxygen tensions, with lower 
levels in tissues than in blood, which are further reduced during inflammation. To 
function under hypoxic conditions, innate immune cells increase anaerobic adenos-
ine triphosphate (ATP) generation by upregulating glycolytic enzymes and glucose 
transporters.1–5 Hypoxia also, however, has a plethora of additional effects on innate 
immune responses.
Low oxygen levels act on vascular endothelial cells to upregulate adhesion molecules 
and chemokines, attracting circulating monocytes and neutrophils.6–11  Neutrophils and 
monocytes upregulate adhesion molecules, such as intercellular adhesion molecule 1 
(ICAM-1) and CD18/CD11b as they reach hypoxic regions, promoting their arrest and 
transendothelial or transepithelial migration toward the site of the inflammation.2,12 
Hypoxia also acts to retain myeloid cells at the site of injury by upregulating factors 
that inhibit migration.2,3,5,13–16
Hypoxia tends to potentiate inflammatory functions and has a prosurvival effect in 
neutrophils, monocytes, and eosinophils.4–5,15,17,18 The ability of innate immune cells to 
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survive and function effectively under hypoxic conditions is 
crucial for host defense in tissues. Immune cell apoptosis is, 
however, an important means of resolving inflammation; pro-
longed survival and activation of myeloid cells under hypoxic 
conditions is likely to play a major role in chronic inflamma-
tion, contributing to diseases such as chronic obstructive pul-
monary disease, asthma, and rheumatoid arthritis (RA).19–23
Lack of oxygen and a reduction in oxidative phosphoryla-
tion, in favor of less efficient glycolysis, might be expected 
to reduce ATP availability and impair cellular functions; 
however, there is evidence that cardiac hypoxia inducible 
factor (HIF) expression can increase ATP availability despite 
inducing a glycolytic switch.24 This may also be the case 
in myeloid cells, with hypoxia enhancing many effector 
functions. Glycolysis is critical for ATP production by myel-
oid and endothelial cells even under normoxic conditions.25,26 
Inhibition of glycolysis reduces endothelial cell proliferation 
and impairs formation of lamellipodia, causing a defect in 
directional migration and vessel formation.26 Potentially, 
therefore, glycolysis (and its upregulation by hypoxia) may 
promote migration of myeloid cells.
Hypoxia upregulates Fc and complement receptors on 
macrophages and neutrophils, thereby enhancing phago-
cytosis.27–32 It also promotes the release of antimicrobial 
mediators, such as β-defensin by macrophages and elastase 
by neutrophils.33–35 Monocytes and macrophages upregu-
late proinflammatory cytokines, such as tumor necrosis 
factor α (TNFα), interferon γ (IFNγ), interleukin (IL)-1β, 
and several neutrophil chemoattractants in hypoxia, while 
downregulating chemokines associated with adaptive 
immunity.2,3,31,36–38
Macrophages precultured in hypoxia are more effective 
at inducing ovalbumin-specific CD8 T-cell responses, due to 
the upregulation of major histocompatibility complex (MHC) 
class I and costimulatory molecules, but they also produce 
arginase, which inhibits CD4 T-cell responses.31,39,40
Many effects of hypoxia are mediated by release of HIFs 
from suppression by the oxygen-dependent hydroxylases. 
These comprise prolyl hydroxylases (PHDs), which target 
them for degradation, and the asparaginyl hydroxylase, factor 
inhibiting HIF, which inhibits HIF transcriptional activity. 
Many immune-related genes are regulated by HIF, either 
directly, via binding of HIF to a HIF-responsive element 
(HRE) in the promoter region, or indirectly, via HIF-mediated 
induction of other signaling molecules and transcription 
factors, such as NF-κB. Effects of HIF signaling in innate 
immune cells in response to hypoxia and other stimuli are 
summarized in Figure 1.
Other mechanisms also play a role in hypoxia signaling; 
for  example, mitochondrial-derived reactive oxygen species 
stabilize HIFs and also activate other transcription factors, 
such as activator protein-1 (AP-1), which induces CXC-
chemokine ligand (CXCL) 8 in hypoxic macrophages.37,38,41–43 
Hypoxia also reduces activity of the Jumonji histone dem-
ethylases, resulting in increased methylation of histone H3 
residues in the promoter regions of chemokine ligand 2 
(CCL2), chemokine (C-C motif) receptor 1 (CCR1), and 
CCR5, repressing their transcription by macrophages.44
Though research so far has focused predominantly on 
myeloid cells, there is also some evidence of the effects of 
hypoxia on other aspects of innate immunity. For instance, 
mice with chronic hypoxia-induced pulmonary hypertension 
have reduced natural killer (NK) cell numbers, cytotoxicity, 
and IFNγ production.45 Hypoxic NK cells downregulate the 
key cytotoxic mediators granzyme B and perforin and lose 
their ability to upregulate activating receptors in response to 
cytokines, thereby reducing their ability to recognize and kill 
infected or abnormal cells.46,47
In addition to the effects of hypoxia on innate immune 
responses to infection, hypoxia can also have direct effects 
on the pathogens themselves, such as modulating the expres-
sion of virulence factors,48 but this is beyond the scope of 
this review.
Roles of HIFs in neutrophil  
responses to hypoxia
Neutrophils are inherently adapted to low oxygen tensions, 
with few mitochondria and reliance on glycolysis for much 
of their energy demand even under normoxic conditions.25
While HIF1A messenger RNA (mRNA) is present in 
freshly isolated neutrophils, HIF-1α protein is not expressed 
in unstimulated cells. It can be induced by hypoxic  culture, the 
iron chelator desferrioxamine, or the competitive hydroxylase 
inhibitor dimethyloxalylglycine (DMOG).5,49 When cultured 
in hypoxia, neutrophils upregulate the glycolytic HIF-1α 
target genes glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and phosphoglycerate kinase (PGK), which may 
serve to provide additional glycolytic capacity for enhanced 
effector function.5 Hypoxic induction of Pgk expression is 
reduced but not abolished in Hif1a−/− neutrophils, suggesting 
that both HIF-1α and other factors (possibly HIF-2α) are 
involved in its induction. ATP levels are substantially reduced 
in Hif1a−/− neutrophils and macrophages, reflecting the central 
role of HIF-1α in regulation of metabolic activity.50
Expression of the cathelicidin-related antimicrobial 
 peptide (CRAMP) is upregulated by hypoxia and in 
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 neutrophils lacking the von Hippel-Lindau protein (VHL) 
(involved in the proteasomal degradation of HIF), whereas 
Hif1a−/− neutrophils express lower levels of CRAMP and 
display reduced ability to breakdown artificial substrates for 
antimicrobial proteases.51 HIF-1α also promotes extracellular 
bacterial killing by inducing formation of neutrophil extra-
cellular traps.52 Furthermore, neutrophil hypoxic survival is 
mediated by HIF, with Hif1a−/− neutrophils displaying a fail-
ure of hypoxia-mediated apoptosis suppression.5,49 In wild-
type (WT), but not Hif1a−/− neutrophils, hypoxia reverses the 
decline in nuclear factor (NF)-κB and IκB kinase (IKK)-α 
levels observed during culture and maintains DNA-binding 
activity of NF-κB family members, which is essential for 
hypoxic survival.
HIF-2α is also expressed by human and murine neutro-
phils and its expression is upregulated by hydroxylase inhibi-
tors, bacteria or lipopolysaccharide (LPS).53 The respiratory 
burst, phagocytosis, chemotaxis, LPS-induced receptor 
upregulation and constitutive apoptosis are unaffected by 
deletion of Hif2a. However, Hif2a−/− inflammatory neutro-
phils derived from bronchoalveolar lavage (BAL) fluid of 
LPS-challenged mice express lower levels of the antioxidant 
enzyme catalase than WT neutrophils and display increased 
apoptosis in response to nitrosative stress.
While circulating leukocytes that are attracted to a site of 
inflammation initially upregulate HIF in response to hypoxia, 
cells exposed to chronic hypoxia may respond differently 
due to the activation of negative feedback mechanisms. For 
instance, hypoxia is reported to induce HIF-mediated tran-
scription of PHD2, PHD3, and VHL – all negative regulators 
of HIF expression.54–57
Although PHDs are generally understood to act upstream 
of HIFs, promoting their degradation, in neutrophils PHD3 
may function downstream of HIF. PHD3 is upregulated 
during hypoxia; this is significantly impaired in Hif1a−/− 
neutrophils.54 PHD3 does not, however, appear to regulate 
HIF-1α expression, since the hypoxic upregulation of HIF 
target genes is not affected by the deletion of Phd3. Phd3−/− 
neutrophils fail to upregulate the anti-apoptotic protein B-cell 
lymphoma extra-large (Bcl-X
L
), as occurs in hypoxic WT 
neutrophils, and exhibit reduced survival during hypoxia.
Roles of HIFs in monocyte and  
macrophage responses to hypoxia
Hypoxic macrophages upregulate HIF-1α and HIF-2α 
proteins in a phosphatidylinositide 3-kinase (PI3K)/pro-
tein kinase B (AKT)-dependent manner.3,58 In contrast to 
neutrophils, macrophages from Phd3−/− mice exhibit higher 
expression of HIF-1α and NF-κB than WT, produce more 
cytokines, and exhibit enhanced chemotactic and phagocytic 
responses, suggesting that in macrophages, PHD3 is acting 
upstream of HIF-1α to degrade HIF-1α protein.59
As in neutrophils, HIF-1α has an important role in regu-
lating macrophage metabolism under hypoxic  conditions. 
HIF1A-null or small interfering RNA (siRNA)-treated mac-
rophages have reduced basal expression and hypoxic induc-
tion of the glycolytic genes PGK and GLUT1, whereas the 
loss of VHL mimics hypoxic induction.3,50 Release of lactate, 
a marker of glycolytic activity and inflammatory activation, is 
significantly lower in Hif1a−/− macrophages and significantly 
higher in Vhl−/− cells.50 HIF signaling is, in turn, influenced 
by metabolism. For instance, the tricarboxylic acid cycle 
intermediate, succinate, which is generated during aerobic 
respiration and upregulated in response to LPS stimulation, 
inhibits PHD activity, resulting in HIF-1α stabilization and 
Il1b transcription in macrophages.60
Hypoxic upregulation of the adhesion molecule ICAM-1 
is inhibited by siRNA targeted against HIF1A or HIF2A, 
while induction of β-integrins in monocytes is abrogated by 
mutation of the HRE in the promoter of CD18, the subunit 
common to the four known β2 integrin heterodimers.3,12 
Hif1a−/− macrophages display defects in chemotaxis, in their 
ability to penetrate the extracellular matrix, and in homotypic 
adhesion, a process of self-aggregation that amplifies the tis-
sue recruitment of leukocytes.50,61 Hif2a−/− macrophages have 
reduced expression of the chemokine receptors macrophage 
colony-stimulating factor receptor and CXC chemokine 
receptor 4 and the adhesion molecule fibronectin-1, resulting 
in a 50% reduction in migratory and invasive capacities.62
Phagocytosis and intracellular bactericidal activity are 
also regulated by HIFs. Hypoxia induces p38 in macrophages 
and p38 inhibition reverses HIF-1α stabilization and enhance-
ment of phagocytosis.32 HIF-1α induces thrombospondin-1 
and the scavenger receptor CD36, which are involved in the 
recognition of apoptotic cells, therefore hypoxia enhances 
phagocytosis of both bacteria and apoptotic neutrophils – 
effects that are abrogated in the presence of HIF1A-directed 
siRNA.32,63 Killing of intracellular bacteria, such as strep-
tococci and Pseudomonas aeruginosa, is enhanced by iron 
chelators and in Vhl−/− macrophages, but impaired in Hif1a−/− 
macrophages, possibly due to HIF-1α-mediated inducible 
nitric oxide synthase (iNOS) induction.50,51,61
Hypoxia also induces the expression of IFNγ, which 
promotes phagocytosis of opsonized cells by upregulating 
surface levels of the CD11b/CD18 complement receptor 
and the CD16/CD32 Fcγ receptor.31 The Ifng promoter 
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contains a functional HRE and hypoxic induction of IFNγ 
and the associated upregulation of opsonic receptors are 
abolished by mutation of this site or by deletion or siRNA 
knockdown of Hif1a. Hif1a−/− macrophages secrete less 
TNF-α in response to LPS or group A streptococci (GAS) 
and fail to upregulate TNF-α when LPS is administered 
under hypoxic conditions.50,51 HIF-1α also binds to a highly 
polymorphic region of the promoter encoding solute carrier 
family member 1 (Slc11a1), a phagocyte-specific solute 
carrier that induces expression of cytokines, chemokines, 
and MHC class II molecules.64 Allelic variation affects the 
ability of HIF-1α to induce SLC11A1 expression and has 
been associated with susceptibility to various inflammatory 
diseases. HIF-2α also appears to be involved in cytokine and 
chemokine transcription, since the hypoxic upregulation 
of Il1b, Il12, Cxcl2 and Cxcl6 is impaired in Hif2a−/− mac-
rophages while hypoxic expression of CXCL8 is reduced in 
macrophages treated with siRNA targeting Hif2A.3,62
In contrast to its many proinflammatory effects, 
hypoxia also promotes repair mechanisms and macrophage 
suppression of T-cells in a HIF-dependent manner.65  Induction 
of the proangiogenic factors vascular endothelial growth 
factor (VEGF) and adrenomedullin is significantly reduced 
by siRNA targeting either HIF1A or HIF2A.3 Hif1a−/− 
macrophages have reduced basal expression and hypoxic 
induction of VEGF, whereas deletion of VHL induces VEGF 
expression under normoxic conditions.3,50 Plasminogen 
activator inhibitor-1 (PAI-1), which promotes thrombosis 
by inhibiting plasminogen-mediated fibrinolysis, is also 
activated by HIF-1α.66
HIFs can also act as negative regulators of gene 
 expression. For instance, HIF-1α (but not HIF-2α) binds to 
the HRE of the histone deacetylase-2 (HDAC2) promoter 
independently of the HIF-1β subunit and reduces transcrip-
tion by inhibiting binding of Polymerase II.67 Hypoxia, 
therefore, reduces mRNA and protein levels of HDAC2, 
a suppressor of NF-κB-mediated transcription, resulting in 
increased inflammation and corticosteroid resistance.
Hif1a mRNA has a shorter half-life than Hif2a mRNA 
and, following intrapulmonary LPS challenge, Hif1a is rap-
idly upregulated but declines after 24 hours, whereas Hif2a 
expression is delayed but maintained during the resolution 
phase.53,68 HIF-1α and HIF-2α bind to the same promoter 
sequence and the expression of many hypoxia-inducible genes, 
including VEGF, IL1B, CXCL8, GLUT1, ADM (adrenomedul-
lin), CXCR4, and STAT4, can be impaired by siRNA targeted 
against either HIF1A or HIF2A.3 Some target genes, however, 
such as the adenosine A2a receptor (ADORA2A), are only 
regulated by one HIF and not the other, which is thought to 
be due to interaction with different coactivators.3,69
Roles of HIF-1α and HIF-2α  
in macrophage polarization
Although both HIF-1α and HIF-2α are induced by hypoxia, 
other stimuli such as cytokines also influence their relative 
expression levels. For instance, Takeda et al68 reported that 
HIF1-α mRNA and protein are induced during M1 polariza-
tion of macrophages (by IFNγ or LPS), whereas HIF-2α is 
induced during M2 polarization (by IL-4 or IL-13) and is 
decreased by stimulation with LPS or IFNγ. Hif1a−/− mac-
rophages infiltrating tumor spheroids in vitro develop a 
more M2-like profile than their WT counterparts, with lower 
cytotoxicity and decreased production of TNFα, iNOS, and 
IL-6, suggesting that HIF-1α is important for proinflamma-
tory responses.70 The work of Imtiyaz et al62 indicates that 
HIF-2α also has important proinflammatory functions, since 
myeloid-specific Hif2a deletion inhibits in vitro secretion 
of the proinflammatory cytokines IL-1β, IL-6, and IL-12 
in response to a combined IFNγ/LPS stimulus and reduces 
serum levels of IL-1β, IL-12, TNFα, and IFNγ following 
in vivo LPS stimulation.
The relative levels of HIF-1α and HIF-2α may play an 
important role in the regulation of nitric oxide (NO) metabo-
lism by controlling the levels of both iNOS and arginase 
(which competes with iNOS for the L-arginine substrate 
required for NO production). Hif2a−/−macrophages exhibit 
normal hypoxic induction of iNOS (Nos2);  however, both the 
basal expression and hypoxic induction of  arginase 1(Arg1) 
are attenuated.62,68 Conversely, Hif1a deletion dramatically 
reduces hypoxic iNOS induction, but it has a smaller effect on 
arginase expression.68 Similar data was obtained by Kobayashi 
et al,71 who observed an increased iNOS response to LPS in 
cells with a Vhl/Hif2a double knockout (in which HIF-1α is 
stabilized while HIF-2α is absent), while Vhl/Hif1a double 
knockout mice produced more arginase in response to IL-13 
stimulation. In accordance with the altered ratio of iNOS/
arginase, mice lacking myeloid HIF-1α exhibited reduced 
NO production 6 hours after LPS treatment, while those 
lacking HIF-2α exhibited increased NO after 24 hours.68 
Takeda et al68 also demonstrated decreased and increased 
levels of in vitro NO production in IFNγ-stimulated Hif1a−/− 
and Hif2a−/− thioglycollate-elicited peritoneal macrophages 
respectively. However, when Imtiyaz et al62 stimulated bone 
marrow-derived marcophages (BMDMs) with a combination 
of IFNγ and LPS, no difference was observed in NO produc-
tion between Hif2a−/− and WT. The discrepancy between the 
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studies could be explained by many factors, including the 
sourcing of macrophages from different tissues, use of a 
different stimulus, and the apparent dependency of the Hif2a 
phenotype on the level of L-arginine availability.68
Mice with a myeloid-specific Phd2 haplodeficiency 
exhibit greater infiltration of mannose receptor, C type 
1 (MRC1)+ proangiogenic/wound-healing M2-like mac-
rophages, which release arteriogenic factors, following 
femoral artery ligation.72 In comparison to WT macrophages, 
Phd2+/− macrophages isolated at baseline express higher 
levels of M2 genes, such as arginase (Arg1), Cxcr4, 
platelet-derived growth factor beta (Pdgfb), neuropilin 1 
(Nrp1), found in inflammatory zone 1 (Fizz1) and trans-
forming growth  factor beta (Tgfb) and lower levels of the 
M1 genes Il12, Nos2, Il1b, Il6, and Tnfa. However, following 
ligation, WT  macrophages from the ischemic musculature 
 upregulate M2 genes, reaching a similar level to that of 
Phd2+/− macrophages, indicating hypoxia is releasing M2 
genes from PHD2-mediated  suppression. Given the previous 
work indicating an association of HIF-1α with iNOS and 
HIF-2α with arginase expression,68 this data might suggest 
that PHD2  expression favors an M1 response by preferen-
tially targeting HIF-2α for destruction.
Modulation of HIF signaling by 
infection and inflammatory stimuli
While hypoxia regulates HIFs largely at the posttranslational 
level, other factors such as cytokines and infectious agents 
regulate its transcription, resulting in a synergistic effect 
when the stimuli are combined.73–78
The HIF1A promoter contains a binding site for NF–κB 
transcription factors.77 Both the basal transcription and 
induction of HIF1A (but not HIF2A) in response to stimuli, 
such as bacteria, TNF-α, or hypoxia, are dependent on 
NF-κB. Reduced HIF-1α accumulation and target gene 
induction are observed in IKKβ-deficient macrophages 
and in cells treated with siRNA targeting members of 
the NF-κB family.76,77 Hypoxia, in turn, augments NF-κB 
expression, phosphorylation, and target gene induction in 
macrophages and neutrophils.3,5,79–81 Hypoxic induction 
of mRNA encoding IKKα, IKKβ, and p65 is impaired in 
Hif1a−/− cells, while the increase in p65 phosphorylation is 
ablated by the deletion of Hif2a.3,5 IKKβ and NF-κB1 are 
also directly regulated by PHDs and factor inhibiting HIF 
respectively.80,82 HIF-1α also binds to the Tlr4 promoter 
and upregulates TLR4 expression, thereby increasing the 
macrophage response to LPS.83
Hypoxia
Cytokines
Microbes
Succinate
Degradation
HIF2AHIF1A
HIF-2αHIF-1α
Bacterial killing:
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      production
•    Arginase → T-cell
     suppression
•    Catalase → resistance
      to nitrosative stress
Figure 1 Role of HiFs in innate immune responses to hypoxia.
Abbreviations: HiF, hypoxia inducible factor; ATP, adenosine triphosphate; iNOS, inducible nitric oxide synthase.
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In addition to activating NF-κB-mediated transcription, 
LPS induces a mammalian target of rapamycin-dependent 
increase in HIF-1α translation in neutrophils and promotes 
succinate-mediated HIF-1α stabilization in macrophages, 
as detailed previously.52,60 Oxygen consumption by bacte-
ria, resulting in cellular hypoxia, has also been proposed 
as a mechanism for the upregulation of HIFs during 
infection.84,85
In vivo models
Immune responses in vivo may be influenced by HIF 
expression in both leukocytes and tissue cells, and systemic 
modulation of HIF expression affects both. Myeloid-specific 
knockouts of HIF signaling components, however, have 
permitted elucidation of the innate immune cell-intrinsic 
effects of hypoxia and HIFs.
Administration of the hydroxylase inhibitor DMOG 
delays inflammatory resolution following tail transection in 
zebrafish larvae, due to decreased apoptosis of neutrophils 
and their retention at the site of injury during the resolution 
phase.86 The effects of DMOG were abrogated by injection 
with a hif1b morpholino or by expression of a dominant 
negative form of the zebrafish HIF1A homolog, hif1ab. 
In contrast, mutation of the proline hydroxylation site 
targeted by PHDs, to create a systemic or myeloid-specific 
dominant active form of HIF-1αb, recapitulated the effect 
of DMOG, indicating a role for HIF-1α in delayed inflam-
mation resolution.
In a murine trauma/hemorrhagic shock model, in which 
gut ischemia/reperfusion injury leads to both local and sys-
temic inflammatory responses, Hif1a+/− mice were protected 
against mucosal gut injury and subsequent lung damage, with 
reduced expression of TNFα, IL-1β, and iNOS in the intes-
tinal mucosa and IL-1β in the lung, further demonstrating a 
role for HIF-1α in promoting inflammation in vivo.87
Cramer et al50 crossed mice with floxed Hif1a, Vegf, or Vhl 
with LysM-cre mice to generate strains with myeloid-specific 
deletions of each of these genes, providing important insights 
into the role of HIF in innate immunity. In a model of acute 
skin inflammation, leukocyte infiltration, myeloperoxidase 
production, and edema were reduced in LysM-cre/Hif1a 
mice and increased in LysM-cre/Vhl mice. Likewise, in an 
arthritis model, edema, synovial infiltration, pannus forma-
tion, and cartilage destruction were profoundly reduced in 
LysM-cre/Hif1a mice.
HIF-1α and VEGF upregulation correlates with increased 
disease severity in a mouse model of allergic rhinitis and 
inhibition of HIF using 2-methoxyestradiol attenuates 
VEGF production and inflammation.88 In an OVA-induced 
murine model of allergic airway disease, inflammatory cell 
infiltration, levels of Th2 cytokines (IL-4, IL-5, and IL-13), 
vascular permeability, fibrosis, goblet cell mucus production, 
OVA-specific IgE, and airway hyperresponsiveness were all 
significantly reduced by inhibition of HIF-1α or VEGF.89–91 
Similar effects were observed in mice with a systemic Hif1b 
deletion or a myeloid-specific Hif1a deletion.89,92,93
Activation of HIFs may be important for antibacterial 
responses. Following subcutaneous GAS administration, 
LysM-cre/Hif1a mice lost more weight than WT mice 
and developed larger necrotic skin lesions, containing 
approximately 1,660-fold more bacteria.51 Bacterial counts 
in blood and spleen were also increased, indicating greater 
systemic spread of infection. Similarly, HIF-1α-mediated 
induction of CRAMP in keratinocytes protects against induc-
tion of skin lesions by GAS and approximately three-fold 
more bacteria were found in the skin ulcers of mice with a 
keratinocyte-specific deletion of Hif1a.94
Conversely, treatment with the HIF agonist mimosine 
reduced lesion size by 50% following subcutaneous S. aureus 
challenge.95 However, mice infected intraperitoneally with a 
mutant strain of S. aureus (SCV) that does not activate HIF-1α 
survive, whereas those infected with the WT strain have 100% 
mortality except when given the HIF-1α inhibitor 17-N-
allylamino-17-demethoxygeldanamycin (17-DMAG).84 This 
demonstrates the fine balance between controlling  infection 
and avoiding excessive and deleterious inflammation.
Mice with a myeloid-specific deletion of Hif2a exhibit 
greater survival, reduced proinflammatory cytokine produc-
tion and less severe hypothermia and cardiac dysfunction 
during LPS-induced endotoxemia.62 Deletion of Hif2a 
also decreases macrophage infiltration in a thioglycollate-
induced model of peritonitis and neutrophil infiltration in 
the 12-O-tetradecanoylphorbol-13-acetate-induced model 
of acute skin inflammation.
Overexpression of the dominant active zebrafish HIF2a 
ortholog, hif2aa, did not affect neutrophil recruitment in 
the tail injury model described previously, but it did delay 
the resolution of neutrophilic inflammation.53 Conversely, 
in a neutrophil-mediated LPS-induced model of acute lung 
injury, mice with a myeloid-specific Hif2a deletion displayed 
normal recruitment of neutrophils to the lung, but the clear-
ance was more rapid, with reduced neutrophil counts after 
48 and 72 hours, increased neutrophil apoptosis, and reduced 
markers of lung injury.53
Although the majority of evidence supports a role for 
HIFs predominantly in promoting inflammation, they may 
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have anti-inflammatory roles under certain circumstances. 
For instance, renal F4/80+ cell (macrophage) accumulation in 
a unilateral ureteral obstruction-induced kidney injury model 
is increased in Vhl−/− and LysMcre/Vhl mice and decreased in 
Hif−/− and LysMcre/Hif mice (in which both Hif1a and Hif2a 
are deleted), suggesting that HIFs are inhibiting migration 
toward the site of injury.71
HIF signaling also has a complex role in tumor biol-
ogy, including effects on the innate immune response, 
particularly tumor-associated macrophages (TAMs), which 
preferentially accumulate in hypoxic regions of tumors.96 
Roda et al97 demonstrated opposing roles of HIF-1α and 
HIF-2α in tumor angiogenesis in a malignant melanoma 
model. In LysM-cre/Hif1a mice, granulocyte-macrophage 
colony-stimulating factor treatment induced soluble VEGF 
receptor, but not VEGF, resulting in a greater reduction in 
tumor growth and vascularization. In contrast, myeloid Hif2a 
deletion resulted in increased expression of VEGF, but not 
soluble VEGF receptor, and abrogated the granulocyte-
macrophage colony-stimulating factor-induced reduction in 
tumor growth and angiogenesis observed in control mice. In 
a murine model of breast cancer, targeted deletion of Hif1a in 
myeloid cells reduced tumor growth, despite Vegf expression 
and vascularization remaining unchanged, perhaps due to 
the release of T-cells from HIF1-α-dependent suppression by 
macrophages.65 Hypoxia within the tumor microenvironment 
also confers on myeloid-derived suppressor cells (MDSC) 
the ability to suppress T-cell proliferation and IFNγ produc-
tion and promotes their differentiation into macrophages 
expressing Il10, Il12, Nos2, Arg1, and Il6.96 Stabilization of 
HIF by desferrioxamine treatment mimics the enhancement 
in suppressive capacity, whereas Hif1a−/− MDSC are poor 
suppressors of T-cell proliferation.
The role of hypoxia and HIFs in macrophage polarization 
in the context of tumor biology remains subject to debate. 
Laoui et al98 suggest that hypoxia is not an important driver 
of macrophage polarization, as it induces HIF-1α and HIF-2α 
simultaneously, therefore promoting the expression of fac-
tors associated with both M1 and M2 responses. Tumors 
of PHD2+/− mice, in which tumor oxygenation is increased, 
display a similar relative abundance of MHCIIhi and MHCIIlo 
TAM subsets (corresponding to M1 and M2 phenotypes, 
respectively) to that seen in WT mice, and the expression of 
hypoxia-regulated genes associated with both M1 and M2 
responses is reduced in TAM infiltrating PHD2+/− tumors.
Data is also beginning to emerge regarding the role of 
other components of the HIF signaling pathway, such as 
PHDs. For example, in an LPS-induced acute lung injury 
model, where rapid neutrophil influx is followed by resolu-
tion, Phd3−/− and WT mice recovered equally well in nor-
moxia. With coexisting hypoxia, however, Phd3−/− mice had 
lower BAL neutrophil counts and higher neutrophil apopto-
sis.54 Increased apoptosis and reduced neutrophil numbers 
were also observed in bowel submucosa following dextran 
sulfate sodium-induced colitis, a neutrophil-dominated 
inflammatory model that involves tissue hypoxia. In a fatal 
model of abdominal sepsis, however, Phd3−/− mice exhibited 
increased macrophage proinflammatory cytokine produc-
tion and decreased survival, due to an overwhelming innate 
immune response.59
HIF-hypoxia signaling in human  
infectious and inflammatory disease
Hypoxia and HIF activation are features of many human 
diseases, including infection, cancers, and a variety of 
inflammatory conditions. Immune cells are an important 
feature of these conditions, as are the tissue cells, and their 
relative and context-specific expression of the HIF pathway 
components may modify clinical outcomes. In skin biopsy 
samples from patients with a variety of cutaneous infec-
tions (including Gram-positive and Gram-negative bacteria, 
parasites, and viruses), a strong nuclear HIF-1α signal is 
detected in keratinocytes, dermal capillaries, neutrophils, 
lymphocytes, and macrophages, which is absent in uninfected 
biopsies.84 Biopsies from damaged intestinal mucosa of 
patients with inflammatory bowel disease exhibit increased 
HIF-1α expression in lamina propria macrophages, compared 
to those from undamaged sections.63 The level of HIF-1α in 
damaged mucosa correlates with the expression of the scav-
enger receptor CD36, suggesting that HIF-1α might promote 
macrophage phagocytosis of microbes and/or apoptotic cells 
within the colon.
HIF-1α is also found in central hypoxic regions of 
human atherosclerotic plaques and colocalizes with Unc5b 
and netrin-1, proteins that are induced in macrophages by 
hypoxia and low-density lipoprotein, promoting cell survival 
and inhibiting migration away from the plaque.15 siRNA 
knockdown of HIF1A in U937 monocytic cells inhibits 
foam cell formation and reduces the expression of 57 of 
the 70 atherosclerotic genes that are induced by oxidized 
low-density lipoprotein, including PTGS2, IL1B, ICAM1, 
and VCAM1, suggesting that myeloid HIF-1α may have an 
important role in atherosclerosis.99
HIF-2α expression is increased in peripheral blood 
neutrophils of inflammatory arthritis patients compared to 
those from healthy controls.53 Strong nuclear HIF-2α and 
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cytoplasmic VEGF immunostaining is also found in both 
neutrophils and neovasculature in lesions of patients with 
pyoderma gangrenosum, an inflammatory skin condition 
thought to involve a defect in resolution of neutrophilic 
inflammation following an inflammatory stimulus.100
Although hypoxia might be expected to activate HIF 
equally in all cell types present in diseased tissue, this is 
not always the case. HIF2-α is expressed in neutrophils 
infiltrating the airway of chronic obstructive pulmonary dis-
ease patients, but not in the epithelium.53 Likewise, HIF-2α 
protein is expressed in TAMs in the majority of uterine 
cervical cancer specimens, whereas ,10% of specimens 
exhibit tumor cell HIF-2α expression.101 TAMs infiltrating 
lung tumors also exhibit strong HIF-2α immunostaining 
in the absence of HIF-2α expression in the tumor cells 
themselves.102 The frequency of clusters of HIF-2α+ TAM 
in breast carcinomas correlates with increased density of 
microvessels and appears to be associated with a reduced 
overall survival rate.103
In cervical cancer patients, the overall macrophage 
count in tumor biopsies does not affect the chance of 
disease-free survival; however, the higher the percentage 
of tumor-associated macrophages that express HIF2α, the 
greater the risk of local recurrence and the lower the prob-
ability of disease-free survival following radiotherapy.101 
In many types of cancer, including breast, ovarian, colon, 
and pancreatic adenocarcinomas, HIF-1α and HIF-2α are 
expressed in the tumor cells themselves.102 This might 
induce factors, such as chemokines, that attract monocytes 
and MDSC and promote their differentiation into immuno-
suppressive macrophages that inhibit T-cell responses, as 
evidenced by murine models. Urothelial carcinomas with 
higher expression of HIF-1α in tumor cells exhibit higher 
TAM infiltration and these patients have a reduced disease-
free survival rate.104
HIF1A, HIF2A, PHD2 and PHD3 transcripts are 
increased in peripheral blood neutrophils of RA patients.53,54 
HIF-1α is highly expressed in synovial fibroblasts and 
infiltrating macrophages in the inflamed RA joint, where 
it enhances TNF-α- and IL-1β-driven activation of the p38 
and extracellular signal-regulated kinase signaling pathways, 
resulting in increased IL-33 expression.105,106 IL-33, in turn, 
upregulates HIF-1α expression in synovial fibroblasts.105 Syn-
ovial fibroblasts derived from osteoarthritis or RA patients 
subcutaneously engrafted into immunodeficient mice induce 
significantly greater myeloid cell infiltration and angiogenesis 
than fibroblasts derived from healthy individuals.107 This 
effect is dependent on both HIF and VEGF, since it can be 
reversed by Hif1a siRNA or by pharmacological inhibition 
of either HIF-1α or VEGF.
Chronically low levels of oxygen may result in the down-
regulation of HIFs under certain circumstances. For example, 
pO
2
 is reduced in the skin of systemic sclerosis patients, 
yet HIF-1α expression in epidermal keratinocytes is lower 
than that of controls, perhaps due to increased PHD levels, 
following induction of negative feedback loops.54,55,57,108
Patients with mutations in components of HIF signaling 
pathways are beginning to shed light on their role in humans. 
Neutrophils from erythrocytosis patients with a gain of func-
tion mutation in HIF2A express higher levels of the target 
genes PAI1 and PHD3 and undergo lower rates of apoptosis 
ex vivo; however, phagocytosis and respiratory burst are 
unaffected.53 Neutrophils derived from patients who are 
heterozygous for a mutation in the VHL gene exhibit lower 
rates of apoptosis and enhanced bacterial phagocytosis under 
normoxic conditions, resembling the phenotype normally 
seen in hypoxia, indicating the importance of proteasomal 
degradation in HIF regulation in human neutrophils.109
Future perspectives  
and therapeutic potential
Given the large number of inflammatory diseases in which 
both hypoxia and HIF upregulation occur, and the important 
role of HIF in determining inflammatory responses, targeting 
the HIF pathway may be a promising avenue for therapies, 
although a number of important issues require addressing.
Chronic hypoxia is a feature of many human diseases, 
yet most research so far has focused on acute responses. One 
important area for future study will be comparing the effects 
of acute versus chronic hypoxia and investigating the role of 
negative feedback mechanisms such as HIF-mediated induc-
tion of PHD and VHL transcription in chronic activation of 
the HIF/hydroxylase pathway.
More detailed studies of the effects of hypoxia on circulat-
ing leukocytes compared with resident immune cells derived 
from different tissues are also warranted. For instance, 
specialized populations of macrophages exist in tissues, 
which may well differ from each other and from circulating 
monocytes in their responses to hypoxic and inflammatory 
stimuli. Given that certain organs, such as the lungs, have 
a higher basal level of oxygen than others, macrophages 
derived from these tissues may exhibit greater responses 
when exposed to hypoxia, due to lower HIF-mediated 
transcription of negative regulatory proteins. Furthermore, 
the study of hypoxic responses and HIF signaling in the 
innate immune system has largely focused on monocytes, 
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macrophages, and neutrophils, whereas research into other 
cell types, such as ILCs, eosinophils, and basophils, has been 
somewhat limited.
Efficacy of HIF-1α inhibition in dampening asthmatic 
inflammation has recently been demonstrated in vivo, sug-
gesting that inhibition of HIF signaling could be beneficial 
in chronic inflammatory diseases.89–91 However, given the 
importance of HIF-1α for antimicrobial responses, care must 
be taken to ensure that treatments directed at the HIF pathway 
do not result in susceptibility to infection.
Pharmacological augmentation of HIF-1α activity by 
mimosine has been proposed as a means of boosting innate 
immune responses and promoting bacterial clearance during 
infection, since mimosine was found to enhance myeloid 
cell bactericidal activity and to inhibit the development 
of necrotic skin lesions following S. aureus challenge 
in mice.51,95
Augmentation of either HIF-1α or HIF-2α also enhances 
angiogenesis and wound healing, which may be beneficial 
in diabetes or ischemic disease.110,111 However, it is not clear 
whether this can be done safely in humans without  inducing 
excessive inflammation, which could exacerbate tissue dam-
age or induce shock.
HIF-1α is upregulated more rapidly than HIF-2α and 
appears to be more important for the acute response to 
infection, whereas HIF-2α expression dominates during the 
resolution of inflammation.53,68 Therefore, the targeting of 
HIF-2α might be useful in dampening chronic inflammation 
while preserving acute responses. The HIF-2α Per-Arnt-
Sim domain contains a cavity that will accommodate small 
molecule ligands which modulate its ability to form active 
heterodimers with HIF-1β, and thus provides an avenue for 
potential pharmacological manipulation.112 However, further 
investigation into the regulation of HIF-2α and the immune 
functions it modulates (and how these differ from HIF-1α) 
is required to determine the likely effects of modifying its 
expression or activity.
Suppression of downstream targets of HIF might also be 
a means of delivering therapies that target specific aspects 
of the hypoxic response while preserving those that are 
protective. PHD3 has been suggested as a therapeutic target in 
neutrophils, owing to its specific effects on hypoxic survival 
in this cell type. Evidence from animal models indicates 
that the inhibition of PHD3 would preserve  neutrophil anti-
microbial function, but encourage the resolution of neutro-
philic inflammation in hypoxic tissues once the infection is 
cleared.54 However, it is important to consider the impact of 
any potential therapy targeting PHD3 on other cell types, 
as its role in macrophages appears to be different to that in 
neutrophils.
While modulation of the HIF pathway has had beneficial 
effects in animal models, further work is required to deter-
mine the most appropriate way of manipulating the pathway 
to promote resolution of infections and to treat inflammatory 
diseases without causing deleterious side effects. Nonethe-
less, the crucial role of HIFs in controlling innate immune 
responses, in response to hypoxia as well as other factors, 
makes this pathway a promising target for further investiga-
tion and potential therapies.
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